RxDoctor Payments Data

Marializa Godoy Jackson, APRN

Psychiatric/Mental Health · Chesterfield, MINPI 1306536545

Payments from drug & device makers

$2,483in general payments, 2019–2025

Across 29 payments — averaging $85.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$801
  • Otsuka America Pharmaceutical, Inc.$613
  • Neurocrine Biosciences, Inc.$578
  • Braeburn Inc.$125
  • Axsome Therapeutics, Inc.$125
  • E.r. Squibb & Sons, L.L.C.$125
  • plus $116 from 1 others

What the payments were for

  • Food & beverage$2,37296%
  • Education$1114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,483 in reported general payments places this provider in the 75th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$20,027
Medicare patients
91
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine25$144,506
RexultiBrexpiprazole45$42,229
Memantine Hcl264$8,528
Donepezil Hcl232$6,522
Sertraline Hcl239$6,431
Ramelteon68$5,702
Duloxetine Hcl106$4,708
Buspirone Hcl257$3,791
Mirtazapine121$3,192
Quetiapine Fumarate148$3,000
Fluoxetine Hcl94$2,216
Olanzapine50$1,560
Divalproex Sodium36$1,184
Risperidone43$605
Trazodone Hcl50$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$801$144,50625 claims
Otsuka America Pharmaceutical, Inc.Rexulti$613$42,22945 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Chesterfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →